



Food and Drug Administration
Rockville MD 20857

APR 8 2005

Re: Geodon
Docket No.: 03E-0259

The Honorable Jon Dudas
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office
Box Pat. Ext.
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Dudas:

This is in regard to the application for patent term extension for U.S. Patent No. 4,831,031, filed by Pfizer, Inc., under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for Geodon, the human drug product claimed by the patent.

The total length of the regulatory review period for Geodon is 3,933 days. Of this time, 2,511 days occurred during the testing phase and 1,422 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: May 3, 1990.

FDA has verified the applicant's claim that the date the investigational new drug application became effective was on May 3, 1990.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: March 17, 1997.

FDA has verified the applicant's claim that the new drug application (NDA) for Geodon (NDA 20-825) was initially submitted on March 17, 1997.


3. The date the application was approved: February 5, 2001.

FDA has verified the applicant's claim that NDA 20-825 was approved on February 5, 2001.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" being the most prominent.

Jane A. Axelrad

Associate Director for Policy
Center for Drug Evaluation and Research

cc: Grover P. Fuller, Jr.
Pfizer, Inc.
Legal Division
235 East 42nd Street
New York, NY 10017